SGLT2 Inhibitors and Long-Term Outcomes After AKI - PubMed
8 days ago
- #acute kidney injury
- #SGLT2 inhibitors
- #renal outcomes
- Study investigates SGLT2 inhibitors (empagliflozin) for improving long-term outcomes in post-AKI survivors.
- Multicenter RCT with 200 severe AKI survivors (eGFR ≥20 ml/min), randomized to empagliflozin 10 mg/d or placebo for 1 year.
- Primary outcome (MAKE365) showed no significant difference between groups (35% empagliflozin vs. 36% placebo, P=0.82).
- Empagliflozin significantly reduced recurrent AKI (34 vs. 66 events per 100 person-years; IRR 0.51, 95% CI 0.31-0.84, P=0.008).
- Conclusion: Empagliflozin did not reduce MAKE365 but may lower recurrent AKI risk in post-AKI patients.